AMLX News and Press, Amylyx Pharmaceuticals Inc. From 03/18/24

2024-03-18 10:00:18 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Johnson & Johnson, Boston...

2024-03-18 09:35:20 ET More on etc. Why 11%-Yielding BIZD's Run Of Beating The S&P 500 Is Likely Over Northwest Healthcare: 3 Takeaways From Q4 Results Arbor Realty: 13.3% 'Sucker Yield,' 3 Better Big-Dividend Strategies Nasdaq, S&P, and Dow advance a...

- Dr. Zeiher brings more than 20 years of drug development experience in areas with serious unmet treatment needs at companies including Astellas Pharma, Pfizer, Eli Lilly and Company, and Merck Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Com...

2024-03-12 08:28:49 ET More on Pre-market losers & stocks. Renalytix approached by potential buyer, stock rallies 28% Renalytix surges after Medicare draft decision on lead product Seeking Alpha’s Quant Rating on ASLAN Pharmaceuticals Historical ea...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - March 11, 2024) - Faruqi & Faruqi, LLP, a leading national s...

2024-03-09 00:20:00 ET Summary The ALS drug (Relyvrio) had been put through a Phase II trial by its developer, Amylyx. Amylyx was already working on a Phase III trial, and they committed to withdrawing the drug if this trial showed no efficacy. Just like with the recent approv...

2024-03-08 07:36:00 ET More on Amylyx Pharmaceuticals Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2023 Earnings Call Transcript Amylyx climbs after Q4 revenue beat and pipeline update Seeki...

- PHOENIX Study Did Not Meet Prespecified Primary or Secondary Endpoints - Data From 664-Participant Study Reinforce That AMX0035 is Generally Safe and Well-Tolerated - Within the Next Eight Weeks, Amylyx Will Continue to Engage With Regulatory Authorities and the ALS Community ...

2024-02-23 17:05:41 ET Summary Amylyx Pharmaceuticals' stock has rebounded by 50% since a rating downgrade in November, reflecting investor relief after Q4 earnings were in line with expectations. The company provided an earlier timeline for Phase 3 PHOENIX trial data, which will ...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has granted stock options and restricted stock units (“RSUs”) to Linda Arsenault, the Company’s newly appointed Chief Human Resources Officer. The Com...